SUTRO BIOPHARMA INC. - COMMON STOCK

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

11 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

04 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

21 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

13 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

22 Oct 2023 03:25:00 By Nasdaq GlobeNewswire

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

16 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

10 Aug 2023 15:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

26 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

03 Jun 2023 15:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

15 May 2023 07:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

27 Apr 2023 15:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

18 Apr 2023 12:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

30 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer  

28 Feb 2023 07:00:03 By Nasdaq GlobeNewswire